Literature DB >> 27928779

How Antibiotics Should be Prescribed to Hospitalized Elderly Patients with Community-Acquired Pneumonia.

Forest W Arnold1.   

Abstract

Elderly patients hospitalized with community-acquired pneumonia (CAP) should be administered antimicrobials in the emergency department prior to transfer to the ward or intensive care unit (ICU). For ward patients, a β-lactam with a macrolide or a respiratory fluoroquinolone alone should be given to cover typical and atypical pathogens. For ICU patients, a β-lactam with either a macrolide or a fluoroquinolone should be given. Other regimens are indicated if methicillin-resistant Staphylococcus aureus or Pseudomonas aeruginosa is a concern. Patients who are hemodynamically stable and can tolerate oral intake can be considered for switch therapy as well as discharge if other co-morbidities are stable and a safe disposition plan exists. A number of special concerns for the elderly include noting adverse effects from antimicrobials, being watchful of comorbidity exacerbations, and vaccinating for pneumococcus and influenza.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27928779     DOI: 10.1007/s40266-016-0423-9

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  33 in total

1.  Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality.

Authors:  Vicente F Corrales-Medina; Daniel M Musher; George A Wells; Julio A Chirinos; Li Chen; Michael J Fine
Journal:  Circulation       Date:  2012-01-04       Impact factor: 29.690

2.  Association Between Noninvasive Ventilation and Mortality Among Older Patients With Pneumonia.

Authors:  Thomas S Valley; Allan J Walkey; Peter K Lindenauer; Renda Soylemez Wiener; Colin R Cooke
Journal:  Crit Care Med       Date:  2017-03       Impact factor: 7.598

3.  Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia.

Authors:  P P Gleason; T P Meehan; J M Fine; D H Galusha; M J Fine
Journal:  Arch Intern Med       Date:  1999-11-22

4.  Comparative effectiveness of linezolid and vancomycin among a national veterans affairs cohort with methicillin-resistant Staphylococcus aureus pneumonia.

Authors:  Aisling R Caffrey; Haley J Morrill; Laura A Puzniak; Kerry L Laplante
Journal:  Pharmacotherapy       Date:  2014-01-13       Impact factor: 4.705

5.  Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis.

Authors:  N Maimon; C Nopmaneejumruslers; T K Marras
Journal:  Eur Respir J       Date:  2008-01-23       Impact factor: 16.671

6.  Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database.

Authors:  Richard B Brown; Paul Iannini; Peter Gross; Mark Kunkel
Journal:  Chest       Date:  2003-05       Impact factor: 9.410

7.  Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database.

Authors:  Tim C Clayton; Mary Thompson; Tom W Meade
Journal:  Eur Heart J       Date:  2007-12-06       Impact factor: 29.983

8.  Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia.

Authors:  J A Ramirez; L Srinath; S Ahkee; A Huang; M J Raff
Journal:  Arch Intern Med       Date:  1995-06-26

9.  Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study.

Authors:  Paula Peyrani; Timothy L Wiemken; Robert Kelley; Marcus J Zervos; Daniel H Kett; Thomas M File; Gary E Stein; Kimbal D Ford; Ernesto G Scerpella; Verna Welch; Julio A Ramirez
Journal:  Crit Care       Date:  2014-06-10       Impact factor: 9.097

10.  Cost effectiveness of adherence to IDSA/ATS guidelines in elderly patients hospitalized for Community-Aquired Pneumonia.

Authors:  Michael E Egger; John A Myers; Forest W Arnold; Leigh Ann Pass; Julio A Ramirez; Guy N Brock
Journal:  BMC Med Inform Decis Mak       Date:  2016-03-15       Impact factor: 2.796

View more
  1 in total

1.  Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria.

Authors:  Xiao-Yan Gai; Shi-Ning Bo; Ning Shen; Qing-Tao Zhou; An-Yue Yin; Wei Lu
Journal:  Chin Med J (Engl)       Date:  2019-03-20       Impact factor: 2.628

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.